Monitor for the filing of the preliminary prospectus supplement, which will disclose share count, price range, and expected gross proceeds. Given the lack of disclosed terms, the market impact will depend on final pricing and size, a large offering at a steep discount could pressure shares, while a modest raise at market could be well-received.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $31.06entry
- T+1 · 8mo ago +1.00%α +0.52% · $31.37
- T+5 · 7mo ago +3.80%α +0.18% · $32.24
- T+20 · 7mo ago +5.86%α −4.02% · $32.88
- T+60 · 5mo ago +19.80%α +5.64% · $37.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of shares. The offering is intended to fund commercial readiness for barzolvolimab, clinical development, platform expansion, and general corporate purposes. Exact size, pricing, and terms remain undisclosed and dependent on market conditions.
Key Facts
- Celldex Therapeutics (CLDX) has commenced an underwritten public offering of common stock.
- Underwriters have a 30-day option to purchase up to an additional 15% of shares.
- Proceeds will fund commercial launch readiness for barzolvolimab (if approved), clinical development, platform growth, and general corporate purposes.
- Leerink Partners and TD Cowen are joint bookrunning managers.
- Offering is made under an existing shelf registration (Form S-3, filed Nov 3, 2023).
- No specific number of shares, price, or total offering size has been disclosed.
Financial Impact
Undisclosed amount, dilution and total capital raise will depend on final pricing and share count.
Risk Factors
- Potential for significant dilution if offering is large and priced at a discount.
- Execution risk if market conditions deteriorate, delaying or scuttling the offering.
- No assurance the offering will close or be completed on favorable terms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266968 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers